Market Closed -
Nasdaq
21:30:00 03/05/2024 BST
|
5-day change
|
1st Jan Change
|
2.12
USD
|
+4.95%
|
|
+21.14%
|
+4.95%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
504.6
|
313
|
49.54
|
52.05
|
-
|
-
|
Enterprise Value (EV)
1 |
504.6
|
313
|
49.54
|
52.05
|
52.05
|
52.05
|
P/E ratio
|
-1.95
x
|
-4.77
x
|
-0.83
x
|
-0.85
x
|
-0.73
x
|
-1.73
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
451
x
|
20.6
x
|
2.03
x
|
1.84
x
|
1.64
x
|
0.57
x
|
EV / Revenue
|
451
x
|
20.6
x
|
2.03
x
|
1.84
x
|
1.64
x
|
0.57
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-22.5
x
|
-6.25
x
|
-
|
-0.72
x
|
-0.68
x
|
-0.81
x
|
FCF Yield
|
-4.45%
|
-16%
|
-
|
-138%
|
-146%
|
-124%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
20,894
|
24,395
|
24,526
|
24,554
|
-
|
-
|
Reference price
2 |
24.15
|
12.83
|
2.020
|
2.120
|
2.120
|
2.120
|
Announcement Date
|
17/03/22
|
29/03/23
|
13/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
1.12
|
15.22
|
24.35
|
28.24
|
31.81
|
91.16
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-111.2
|
-62.68
|
-71.93
|
-75.97
|
-85.55
|
-41.72
|
Operating Margin
|
-9,930.09%
|
-411.94%
|
-295.36%
|
-268.99%
|
-268.9%
|
-45.77%
|
Earnings before Tax (EBT)
1 |
-110.1
|
-60.51
|
-65.76
|
-68.95
|
-85.39
|
-41.72
|
Net income
1 |
-110.7
|
-60.51
|
-65.76
|
-68.95
|
-85.39
|
-41.15
|
Net margin
|
-9,887.23%
|
-397.69%
|
-270.04%
|
-244.11%
|
-268.41%
|
-45.14%
|
EPS
2 |
-12.41
|
-2.690
|
-2.440
|
-2.493
|
-2.910
|
-1.223
|
Free Cash Flow
1 |
-22.47
|
-50.08
|
-
|
-72
|
-76
|
-64.5
|
FCF margin
|
-2,006.16%
|
-329.15%
|
-
|
-254.93%
|
-238.89%
|
-70.76%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
17/03/22
|
29/03/23
|
13/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
1
|
2.307
|
3.437
|
4.245
|
5.227
|
5.867
|
6.202
|
5.959
|
6.326
|
6.688
|
6.904
|
7.129
|
7.362
|
7
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-13.16
|
-15.94
|
-13.81
|
-18.36
|
-15.04
|
-15.47
|
-16.82
|
-19.54
|
-17.85
|
-17.71
|
-18.36
|
-18.6
|
-18.68
|
-19.86
|
-21.68
|
Operating Margin
|
-
|
-1,594.5%
|
-598.79%
|
-534.19%
|
-354.2%
|
-296%
|
-286.77%
|
-315.14%
|
-299.53%
|
-280.02%
|
-274.49%
|
-269.44%
|
-262.07%
|
-269.72%
|
-309.71%
|
Earnings before Tax (EBT)
1 |
-87.09
|
-15.99
|
-13.86
|
-18.26
|
-14.47
|
-13.92
|
-15.22
|
-17.97
|
-16.3
|
-16.27
|
-16.85
|
-17.09
|
-17.06
|
-17.94
|
-21.28
|
Net income
1 |
-87.24
|
-15.99
|
-13.86
|
-18.27
|
-14.47
|
-13.91
|
-15.22
|
-17.97
|
-16.3
|
-16.27
|
-16.85
|
-17.09
|
-17.06
|
-17.94
|
-21.28
|
Net margin
|
-
|
-1,599%
|
-600.65%
|
-531.54%
|
-340.97%
|
-266.18%
|
-259.47%
|
-289.76%
|
-273.57%
|
-257.18%
|
-251.96%
|
-247.58%
|
-239.33%
|
-243.65%
|
-304.01%
|
EPS
2 |
-9.170
|
-0.7700
|
-0.6600
|
-0.8700
|
-0.6800
|
-0.4800
|
-0.5700
|
-0.6700
|
-0.6000
|
-0.6000
|
-0.6200
|
-0.6267
|
-0.6000
|
-0.6367
|
-0.7800
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/11/21
|
17/03/22
|
12/05/22
|
10/08/22
|
09/11/22
|
29/03/23
|
10/05/23
|
09/08/23
|
08/11/23
|
13/03/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-22.5
|
-50.1
|
-
|
-72
|
-76
|
-64.5
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
0.05
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
4.11%
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
17/03/22
|
29/03/23
|
13/03/24
|
-
|
-
|
-
|
Last Close Price
2.12
USD Average target price
11.67
USD Spread / Average Target +450.31% Consensus |
1st Jan change
|
Capi.
|
---|
| +4.95% | 52.05M | | -3.79% | 88.14B | | +1.45% | 40.51B | | -15.94% | 31.67B | | +52.66% | 24.62B | | -14.50% | 15.65B | | -14.38% | 12.07B | | -9.12% | 11.97B | | -42.56% | 11.61B | | +4.87% | 8.81B |
Biopharmaceuticals
|